Anthony J. Jaslowski

2.2k total citations
31 papers, 1.2k citations indexed

About

Anthony J. Jaslowski is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Dermatology. According to data from OpenAlex, Anthony J. Jaslowski has authored 31 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 5 papers in Dermatology. Recurrent topics in Anthony J. Jaslowski's work include Cancer Treatment and Pharmacology (9 papers), Lung Cancer Treatments and Mutations (5 papers) and Chemotherapy-related skin toxicity (5 papers). Anthony J. Jaslowski is often cited by papers focused on Cancer Treatment and Pharmacology (9 papers), Lung Cancer Treatments and Mutations (5 papers) and Chemotherapy-related skin toxicity (5 papers). Anthony J. Jaslowski collaborates with scholars based in United States, Germany and Russia. Anthony J. Jaslowski's co-authors include Charles L. Loprinzi, Jeff A. Sloan, Kelli N. Burger, Paul J. Novotny, Shaker R. Dakhil, Nguyet Le‐Lindqwister, Brandi Reeves, Daniel H. Lachance, Arif H. Kamal and Gamini S. Soori and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Anthony J. Jaslowski

31 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anthony J. Jaslowski United States	14	898	255	213	192	159	31	1.2k
Kenji Hashimoto Japan	19	568 0.6×	289 1.1×	124 0.6×	248 1.3×	63 0.4×	54	1.1k
Ravi D. Rao United States	12	588 0.7×	276 1.1×	197 0.9×	130 0.7×	200 1.3×	19	1.2k
Philipp von Breitenbuch Germany	9	458 0.5×	684 2.7×	95 0.4×	178 0.9×	39 0.2×	16	1.6k
Shinji Itoyama Japan	20	478 0.5×	353 1.4×	47 0.2×	192 1.0×	114 0.7×	64	1.3k
Hiroyuki Eda Japan	17	347 0.4×	409 1.6×	204 1.0×	61 0.3×	52 0.3×	37	994
Markus Raderer Austria	20	598 0.7×	197 0.8×	47 0.2×	380 2.0×	58 0.4×	62	1.5k
Anja Derer Germany	18	590 0.7×	348 1.4×	66 0.3×	207 1.1×	100 0.6×	28	1.3k
Cooley G. Pantazis United States	17	187 0.2×	263 1.0×	98 0.5×	138 0.7×	67 0.4×	53	754
Alessandra Nerviani United Kingdom	24	278 0.3×	495 1.9×	136 0.6×	83 0.4×	135 0.8×	49	1.8k

Countries citing papers authored by Anthony J. Jaslowski

Since Specialization

Citations

This map shows the geographic impact of Anthony J. Jaslowski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anthony J. Jaslowski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anthony J. Jaslowski more than expected).

Fields of papers citing papers by Anthony J. Jaslowski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anthony J. Jaslowski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anthony J. Jaslowski. The network helps show where Anthony J. Jaslowski may publish in the future.

Co-authorship network of co-authors of Anthony J. Jaslowski

This figure shows the co-authorship network connecting the top 25 collaborators of Anthony J. Jaslowski. A scholar is included among the top collaborators of Anthony J. Jaslowski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anthony J. Jaslowski. Anthony J. Jaslowski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lin, Po‐Ju, Brian J. Altman, Richard F. Dunne, et al.. (2024). The influence of yoga and cognitive behavioral therapy on mediational relationships between insomnia and cancer-related fatigue: A URCC NCORP RCT in 550 cancer survivors.. Journal of Clinical Oncology. 42(16_suppl). 12015–12015. 1 indexed citations

Jatoi, Aminah, Preston D. Steen, Philip J. Atherton, et al.. (2017). A double-blind, placebo-controlled randomized trial of creatine for the cancer anorexia/weight loss syndrome (N02C4): an Alliance trial. Annals of Oncology. 28(8). 1957–1963. 23 indexed citations

Smith, Sonali M., Brandelyn N. Pitcher, Sin‐Ho Jung, et al.. (2017). Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials. The Lancet Haematology. 4(4). e176–e182. 63 indexed citations

Crozier, Jennifer A., Pooja Advani, Betsy LaPlant, et al.. (2015). N0436 (Alliance): A Phase II Trial of Irinotecan With Cetuximab in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane-Containing Therapy. Clinical Breast Cancer. 16(1). 23–30. 43 indexed citations

Barton, Debra L., Gita Thanarajasingam, Jeff A. Sloan, et al.. (2014). Phase III double‐blind, placebo‐controlled study of gabapentin for the prevention of delayed chemotherapy‐induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, NCCTG N08C3 (Alliance). Cancer. 120(22). 3575–3583. 14 indexed citations

Kottschade, Lisa A., Vera J. Suman, Domingo G. Pérez, et al.. (2012). A randomized phase 2 study of temozolomide and bevacizumab or nab ‐paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma. Cancer. 119(3). 586–592. 64 indexed citations

Reeves, Brandi, Shaker R. Dakhil, Jeff A. Sloan, et al.. (2012). Further data supporting that paclitaxel‐associated acute pain syndrome is associated with development of peripheral neuropathy. Cancer. 118(20). 5171–5178. 127 indexed citations

Loprinzi, Charles L., Ernie Balcueva, Heshan Liu, et al.. (2011). A Phase III Randomized, Double-Blind, Placebo-Controlled Study of Pilocarpine for Vaginal Dryness: North Central Cancer Treatment Group Study N04CA. PubMed. 9(3). 105–112. 9 indexed citations

Kottschade, Lisa A., Vera J. Suman, Thomas Amatruda, et al.. (2010). A phase II trial of nab‐paclitaxel (ABI‐007) and carboplatin in patients with unresectable stage IV melanoma. Cancer. 117(8). 1704–1710. 79 indexed citations

10.

Reeves, Brandi, Shaker R. Dakhil, Jeff A. Sloan, et al.. (2010). Natural history of paclitaxel-associated acute pain syndrome (P-APS): NCCTG trial N08C1.. Journal of Clinical Oncology. 28(15_suppl). 9135–9135. 1 indexed citations

11.

Markovic, S. N., Vera J. Suman, Lisa A. Kottschade, et al.. (2009). A phase II trial of carboplatin (C) and nab-paclitaxel (ABI-007-nab-P) in patients with unresectable stage IV melanoma: Final data from N057E. Journal of Clinical Oncology. 27(15_suppl). 9055–9055. 2 indexed citations

12.

Jatoi, Aminah, Shaker R. Dakhil, Nathan R. Foster, et al.. (2008). Bortezomib, Paclitaxel, and Carboplatin as a First-Line Regimen for Patients with Metastatic Esophageal, Gastric, and Gastroesophageal Cancer: Phase II Results from the North Central Cancer Treatment Group (N044B). Journal of Thoracic Oncology. 3(5). 516–520. 26 indexed citations

13.

Hobday, Timothy J., Phillip J. Stella, Tom R. Fitch, et al.. (2008). N0436: A phase II trial of irinotecan plus cetuximab in patients with metastatic breast cancer and prior anthracycline and/or taxane-containing therapy. Journal of Clinical Oncology. 26(15_suppl). 1081–1081. 13 indexed citations

14.

McWilliams, Robert R., Nathan R. Foster, Fernando Quevedo, et al.. (2007). NCCTG phase I/II trial (N9943) of gemcitabine and pemetrexed in patients with biliary tract or gallbladder carcinoma: Phase II results. Journal of Clinical Oncology. 25(18_suppl). 4578–4578. 3 indexed citations

15.

Alberts, Steven R., Nathan R. Foster, Fernando Quevedo, et al.. (2007). Pemetrexed and Gemcitabine for Biliary Tract and Gallbladder Carcinomas: a North Central Cancer Treatment Group (NCCTG) Phase I and II Trial, N9943. Journal of Gastrointestinal Cancer. 38(2-4). 87–94. 10 indexed citations

16.

Loprinzi, Charles L., John W. Kugler, Debra L. Barton, et al.. (2006). Phase III Trial of Gabapentin Alone or in Conjunction With an Antidepressant in the Management of Hot Flashes in Women Who Have Inadequate Control With an Antidepressant Alone: NCCTG N03C5. Journal of Clinical Oncology. 25(3). 308–312. 69 indexed citations

17.

Kahl, Brad S., Jules H. Blank, Anthony J. Jaslowski, et al.. (2004). Phase II Study of Modified Hyper-CVAD with Rituximab Maintenance for Previously Untreated Mantle Cell Lymphoma: A Wisconsin Oncology Network Study.. Blood. 104(11). 1388–1388. 9 indexed citations

18.

Hoang, Tien, KyungMann Kim, Anthony J. Jaslowski, et al.. (2003). Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer. Lung Cancer. 42(1). 97–102. 54 indexed citations

19.

Lara, Primo N., Martin J. Edelman, James H. Doroshow, et al.. (2000). Salvage gemcitabine (GEM) in platinum-treated non-small cell lung cancer (NSCLC): A phase II California cancer consortium trial. Lung Cancer. 29(1). 58–58. 4 indexed citations

20.

Staskus, Katherine, Ren Sun, George Miller, et al.. (1999). Cellular Tropism and Viral Interleukin-6 Expression Distinguish Human Herpesvirus 8 Involvement in Kaposi’s Sarcoma, Primary Effusion Lymphoma, and Multicentric Castleman’s Disease. Journal of Virology. 73(5). 4181–4187. 202 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact